SMS Pharma Ltd Gets Two Observations From USFDA For Kandivalasa API Facility

The United States Food and Drug Administration (USFDA) conducted a CGMP inspection at SMS Pharmaceuticals Ltd’s Kandivalasa, Vizianagaram, Andhra Pradesh API manufacturing facility from 13th January 2020 to 17th January, 2020.

The inspection ended with Two observations which are procedural in nature and correctable which company believes are minor in nature and no data integrity issues were observed in the inspection.

The Company is committed to meeting the highest quality standards and are further committed to full compliance with CGMP regulations at all our manufacturing facilities. The Kandivalasa Unit is one of our Active Pharmaceutical Ingredients (API) manufacturing facility, and this was the third U.S. FDA inspection. The Company is confident to address the observations raised by the agency satisfactorily and will submit our comprehensive response within the stipulated timeline.

Shares of SMS PHARMACEUTICALS LTD. was last trading in BSE at Rs.48 as compared to the previous close of Rs. 48.25. The total number of shares traded during the day was 846 in over 73 trades.

The stock hit an intraday high of Rs. 48.6 and intraday low of 47.3. The net turnover during the day was Rs. 40852.-Equity Bulls

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.